Novartis | NVS - Net Income


Novartis reported $3.16B in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Amgen USD 1.82B 486M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Bausch Health Companies USD -1.42B 1.31B Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Canopy Growth CAD -157.11M 94.49M Mar/2026
Corcept Therapeutics USD -31.76M 56.05M Mar/2026
Drreddys Laboratories INR 2.21B 9.89B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Glaxosmithkline GBP 1.74B 890.94M Mar/2026
J&J USD 5.53B 299M Jun/2026
Merck USD -4.24B 7.2B Mar/2026
Novartis USD 3.16B 747M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Pacira USD 2.92M 1.28M Mar/2026
Perrigo USD -398.6M 1.02B Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Phibro Animal Health USD 27.46M 932K Dec/2025
Prestige Brands USD 46.7M 22.44M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
Sanofi EUR 1.61B 2.42B Mar/2026
Supernus Pharmaceuticals USD -2.29M 1.81M Mar/2026
Zoetis USD 601M 2M Mar/2026